血清 JKAP 在急性缺血性脑卒中患者中的临床价值。
Clinical value of serum JKAP in acute ischemic stroke patients.
机构信息
Department of Neurology, Lishui Municipal Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Department of Endocrinology, Zhuji People's Hospital of Zhejiang Province, Zhuji, China.
出版信息
J Clin Lab Anal. 2022 Apr;36(4):e24270. doi: 10.1002/jcla.24270. Epub 2022 Mar 10.
BACKGROUND
Jun N-terminal kinase pathway-associated phosphatase (JKAP) regulates neuronal function, T helper (Th) 1/2/17 cell differentiation, and inflammatory process, but its clinical role in acute ischemic stroke (AIS) patients remains unclear. Hence, this study intended to evaluate JKAP level and its relationship with disease severity, Th1, 2, 17 secreted cytokines, adhesion molecules, and prognosis of AIS patients.
METHODS
Serum JKAP of 122 AIS patients and 50 controls was detected by ELISA. For AIS patients only, Th1, 2, 17 secreted cytokines IFN-γ, IL-4, IL-17; TNF-α, ICAM-1, and VCAM-1 were also detected by ELISA.
RESULTS
JKAP was decreased in AIS patients compared with controls (46.350 (interquartile range (IQR): 34.250-59.875) pg/ml vs. 84.500 (IQR: 63.175-113.275) pg/ml, p < 0.001), which could distinguish AIS patients from controls (area under curve (AUC): 0.810, 95% confidence interval (CI): 0.732-0.888). In AIS patients, JKAP negatively linked with the National Institutes of Health Stroke Scale (NIHSS) score (r = -0.342, p < 0.001); besides, it was positively related to IL-4 (r = 0.213, p = 0.018) and negatively associated with IL-17 (r = -0.270, p = 0.003) but not related to IFN-γ (r = -0.146, p = 0.109). Furthermore, elevated JKAP associated with declined TNF-α (r = -0.219, p = 0.015) and ICAM-1 (r = -0.235, p = 0.009) but not related to VCAM-1 (r = -0.156, p = 0.085). Besides, declined JKAP was linked with 2-year recurrence (p = 0.027) and 3-year recurrence (p = 0.010) in AIS patients; while JKAP was not related to 1-year recurrence or death risk (both p > 0.050).
CONCLUSION
JKAP may sever as a candidate prognostic biomarker in AIS patients, indicating its potency for AIS management.
背景
Jun N-末端激酶通路相关磷酸酶（JKAP）调节神经元功能、辅助性 T 细胞（Th）1/2/17 细胞分化和炎症过程，但它在急性缺血性脑卒中（AIS）患者中的临床作用尚不清楚。因此，本研究旨在评估 JKAP 水平及其与疾病严重程度、Th1、2、17 分泌细胞因子、黏附分子以及 AIS 患者预后的关系。
方法
通过 ELISA 检测 122 例 AIS 患者和 50 例对照者的血清 JKAP。仅对 AIS 患者进行 Th1、2、17 分泌细胞因子 IFN-γ、IL-4、IL-17、TNF-α、ICAM-1 和 VCAM-1 的 ELISA 检测。
结果
与对照组相比，AIS 患者的 JKAP 降低（46.350（四分位距（IQR）：34.250-59.875）pg/ml 比 84.500（IQR：63.175-113.275）pg/ml，p<0.001），可以将 AIS 患者与对照组区分开（曲线下面积（AUC）：0.810，95%置信区间（CI）：0.732-0.888）。在 AIS 患者中，JKAP 与美国国立卫生研究院卒中量表（NIHSS）评分呈负相关（r=-0.342，p<0.001）；此外，它与 IL-4 呈正相关（r=0.213，p=0.018），与 IL-17 呈负相关（r=-0.270，p=0.003），但与 IFN-γ无关（r=-0.146，p=0.109）。此外，升高的 JKAP 与 TNF-α（r=-0.219，p=0.015）和 ICAM-1（r=-0.235，p=0.009）呈负相关，而与 VCAM-1 无关（r=-0.156，p=0.085）。此外，在 AIS 患者中，JKAP 降低与 2 年复发（p=0.027）和 3 年复发（p=0.010）相关，而 JKAP 与 1 年复发或死亡风险无关（均 p>0.050）。
结论
JKAP 可能作为 AIS 患者的候选预后生物标志物，表明其在 AIS 管理中的潜力。
Zotero 插件